Population
Tobacco protoplasts, Chinese hamster ovary cells, and yeast cells, as well as in vitro translation lysates
Comparison
Poly+ and poly- luciferase mRNAs generated in… vs mRNAs lacking cap or poly(A) tail
Design
Preclinical
Authors
Loading...
No immediate clinical implications for mRNA therapies; leaves open cap-poly(A) synergy in human cardiovascular models.
The cap and the poly(A) tail are interdependent for optimal mRNA translation function in vivo, suggesting synergistic communication between the two regulatory determinants.
Daniel Gallie (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: